Bristol Myers’ Opdivo fails part two of post-kidney cancer surgery test as competitor Merck touts new survival data

Bristol Myers' Opdivo has failed part two of a post-kidney cancer surgery test, while competitor Merck has announced new survival data for its drug Keytruda. Keytruda has been approved as a postsurgical treatment for resectable kidney cancer and has recently gained new backing in the form of data. In contrast, Bristol Myers' Opdivo, along with Yervoy, failed to significantly reduce relapses compared to a placebo when used after the surgical removal of the kidney in high-risk patients. This development raises questions about the effectiveness of Opdivo in post-kidney cancer surgery situations and highlights the importance of continued research and development in this field.